AiCuris

What AiCuris does

AiCuris Anti-infective Cures AG is a privately held biopharmaceutical company headquartered in Wuppertal, Germany, that develops antiviral therapeutics exclusively for immunocompromised patients — including transplant recipients, patients with malignancies, people living with HIV, and those with autoimmune or inflammatory disorders. Founded in 2006 as a spin-off from Bayer, the company focuses on small-molecule and antisense oligonucleotide drug design, with two distinct proprietary platforms: helicase-primase inhibition (the mechanism behind pritelivir, which is active against HSV strains resistant to nucleoside analogues and foscarnet) and antisense oligonucleotide-mediated inhibition of viral mRNA splicing (the basis of AIC468 for BK virus). The company's commercial portfolio consists of three assets at different stages: PREVYMIS (letermovir), an FDA-approved CMV prevention drug licensed exclusively to MSD/Merck and marketed in 60+ countries, which generates royalty income; pritelivir, a Phase 3 helicase-primase inhibitor for refractory HSV infections in immunocompromised patients that received FDA Breakthrough Therapy Designation and Priority Review with a Q4 2026 PDUFA target date; and AIC468, a Phase 1 antisense oligonucleotide candidate for BK virus reactivation in kidney transplant recipients.

AiCuris operates a licensing- and royalty-driven revenue model, with current cash flows anchored to MSD's global PREVYMIS sales and future revenue expected to accrue from pritelivir commercialization following regulatory approval. The go-to-market approach has historically been partner-led — relying on MSD for PREVYMIS and on academic collaborators (Universitätsklinikum Hamburg-Eppendorf, Universitätsklinikum Erlangen, DZIF) for early-stage discovery through its AiCubator program. In February 2026, Asahi Kasei announced a definitive agreement to acquire AiCuris for approximately €780 million (~$920 million) through its U.S. subsidiary Veloxis Pharmaceuticals, with closing in April 2026. The acquisition provides AiCuris with direct access to Veloxis's transplant-center and renal-disease commercial networks in the United States, and supports Asahi Kasei's strategic goal of ¥300 billion in pharmaceutical sales with 15%+ operating margin by fiscal 2030.

Name

AiCuris

Legal name

AiCuris Anti-infective Cures AG

Website

https://aicuris.com

Company type

Private

Founded year

2006

Operating status

Acquired

Headcount range

51–100 employees

Short description

AiCuris is a German biopharmaceutical company developing novel antiviral therapies — including the marketed PREVYMIS, late-stage pritelivir, and early-stage AIC468 — exclusively for immunocompromised patients such as transplant recipients and people living with HIV, now operating as a subsidiary of Asahi Kasei.

Ownership category

akta.pro rank

Product category

Infectious Disease Therapeutics

NAICS

Health Care and Social Assistance (62)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Transplant & Immunocompromised Host Infections (HLAKAGAM)

akta.pro secondary industry

HIV/AIDS Medicine (HLAKAGAB)

Keywords

• Antiviral therapeutics
• Infectious disease drugs
• Biopharmaceutical research
• Immunocompromised treatments
• Transplant infection therapy

Headquarters

HQ city

Wuppertal

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Royalty income from PREVYMIS: AiCuris receives royalty income from PREVYMIS (letermovir), which is marketed globally by MSD (Merck). PREVYMIS is approved for cytomegalovirus prevention in transplant recipients and is available in over 60 countries with robust annual revenue growth.
2. Future product revenue from pritelivir: Upon FDA approval (PDUFA target Q4 2026), pritelivir is expected to generate significant revenue. Asahi Kasei projects peak revenue from pritelivir exceeding $400 million in the mid-to-late 2030s. The drug received FDA Priority Review designation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

AiCuris discovers and develops novel antiviral therapeutics for immunocompromised patients, including the marketed CMV prevention drug PREVYMIS (letermovir, licensed to MSD), the Phase 3 helicase-primase inhibitor pritelivir for refractory HSV infections, and the Phase 1 antisense oligonucleotide AIC468 for BK virus in kidney transplant patients. The company's pipeline targets high-unmet-need viral infections where standard nucleoside analog therapies fail or do not exist.

Product overview

AiCuris is a biopharmaceutical company focused on developing antiviral therapies for immunocompromised patients. The company's portfolio consists of three main compounds: PREVYMIS (letermovir), a marketed CMV prevention drug licensed to MSD; Pritelivir, a Phase 3 helicase-primase inhibitor for refractory HSV infections with FDA Priority Review status targeting approval in 2026; and AIC468, a Phase 1 antisense oligonucleotide candidate for BK virus in kidney transplant recipients. The company operates with a focus on severe infectious diseases affecting patients with weakened immune systems, particularly transplant recipients and those with hematological malignancies.

Differentiator

Problem solved

Functional benefit

Products and services

• PREVYMIS (letermovir) Antiviral agent approved for prevention of cytomegalovirus (CMV) reactivation in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants and kidney transplants. Marketed globally by MSD (Merck) in over 60 countries. AiCuris receives royalty income from global sales.
• Pritelivir Phase 3 novel helicase-primase inhibitor targeting HSV-1 and HSV-2, developed to treat refractory herpes simplex virus infections with or without resistance in immunocompromised patients. Active against strains resistant to existing nucleoside analog therapies. Receives royalty income via future commercialization through Asahi Kasei's Veloxis Pharmaceuticals.
• AIC468 Phase 1 antisense oligonucleotide (ASO) therapy designed to treat BK virus reactivation in kidney transplant patients by inhibiting splicing of the pre-mRNA encoding the virus' large T-antigen. First-in-class mechanism with no approved alternatives.

Quantifiable outcome

• 62.7% lesion healing rate vs 34.0% for investigator's choice therapy (p = 0.0047)
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered strategic, core and minor.

• German Center for Infection Research (DZIF)strategicStrategic or Co-development Partner · 1 January 2024In 2024, AiCuris and DZIF entered a research collaboration and license option agreement for the identification of novel targets for antiviral therapies and discovery of new active agents for treatment and prophylaxis of infections in immunocompromised patients.
• MSD (Merck & Co.)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2012In 2012, AiCuris entered into an exclusive worldwide license agreement with MSD for its portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (PREVYMIS). This partnership resulted in successful global registration of the drug in major markets. AiCuris receives royalty income from MSD's global sales of PREVYMIS.
• Universitätsklinikum Hamburg-EppendorfminorStrategic or Co-development PartnerAiCubator resident collaborating on a project targeting BKPyV (polyomavirus). The project builds on established workflow from phenotypic screening to mode of action and focuses on key experiments to understand cytotoxicity and selectivity in infected primary cells and complex tissues.
• Universitätsklinikum ErlangenminorStrategic or Co-development PartnerAiCubator resident collaborating on research discovering unique structural and functional properties of the cytomegalovirus-specific nuclear egress complex (NEC), nominating herpesviral NECs as novel potential targets for antiviral therapy.
• Asahi Kasei (via Veloxis Pharmaceuticals)coreOEM/ Whitelabel/ Licensing PartnerAsahi Kasei acquired AiCuris in 2026 for €780 million. The acquisition will be advanced through Asahi Kasei's U.S. subsidiary Veloxis Pharmaceuticals, which has established transplant-center and renal-disease commercial networks for commercialization of AiCuris' pipeline products.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Pfizer: Large-cap pharmaceutical company with antiviral and vaccine franchises including COVID-19 and HIV. Broad incumbent with overlapping infectious disease therapeutics focus.
• AbbVie: Global biopharma with a leading HIV franchise (via Viiv) and historically strong in virology. Comparable positioning in viral infectious diseases for immunocompromised patients.
• GSK: Global pharmaceutical company with extensive anti-infectives portfolio including HIV and CMV therapeutics. Operates broadly in the same infectious-disease therapeutic space as AiCuris.
• Gilead Sciences: Large-cap antiviral leader with strong franchises in HIV, HCV, and CMV (letermovir competitor with PREVYMIS through Merck). Broad incumbent in antivirals competing in adjacent indications to AiCuris.
• Moderna: Major mRNA-based vaccines and therapeutics company with products in infectious disease. Comparable as a biopharma focused on infectious disease therapeutics though differentiated by platform and modality.

Emerging players

• ContraFect: Clinical-stage biotech developing direct lytic agents and monoclonal antibodies for serious infections including antibiotic-resistant bacterial targets. Adjacent infectious disease focus comparable to AiCuris's specialty infectious disease positioning.

Direct peers

• Vir Biotechnology: A clinical-stage immunology company developing antiviral therapies for serious infectious diseases, including immunocompromised populations and HIV. Directly comparable to AiCuris in targeting viral infections with novel mechanisms and serving specialized patient populations.
• Atea Pharmaceuticals: Develops oral, direct-acting antiviral therapies for serious viral infections including HCV, RSV, and COVID-19. Comparable to AiCuris in small-molecule antiviral focus and specialty infectious disease positioning.
• Assembly Biosciences: A clinical-stage biotech developing antiviral therapies, including helicase-primase inhibitors for HSV and HBV. Closely comparable to AiCuris's pritelivir program given overlapping mechanism and indication.
• NanoViricides: A clinical-stage antiviral platform company developing virus-binding nanomedicines for HSV, COVID-19, and other viral infections. Comparable niche antiviral development focus to AiCuris.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/aicuris
• LinkedInlinkedin.com/company/1261913

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AiCuris